1. Home
  2. ADT vs ORKA Comparison

ADT vs ORKA Comparison

Compare ADT & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ADT Inc.

ADT

ADT Inc.

N/A

Current Price

$9.90

Market Cap

7.2B

ML Signal

N/A

Logo Oruka Therapeutics Inc.

ORKA

Oruka Therapeutics Inc.

N/A

Current Price

$93.94

Market Cap

6.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ADT
ORKA
Founded
1874
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.2B
6.4B
IPO Year
2017
1997

Fundamental Metrics

Financial Performance
Metric
ADT
ORKA
Price
$9.90
$93.94
Analyst Decision
Hold
Strong Buy
Analyst Count
4
13
Target Price
$10.00
★ $156.17
AVG Volume (30 Days)
★ 25.0M
904.3K
Earning Date
11-03-2026
11-09-2026
Dividend Yield
★ 2.23%
N/A
EPS Growth
★ 29.63
N/A
EPS
★ N/A
N/A
Revenue
★ $5,128,607,000.00
N/A
Revenue This Year
$2.35
N/A
Revenue Next Year
$2.26
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 4.70
N/A
52 Week Low
$6.03
$25.23
52 Week High
$10.00
$115.52

Technical Indicators

Market Signals
Indicator
ADT
ORKA
Relative Strength Index (RSI) 83.14 47.46
Support Level $6.26 $83.25
Resistance Level $9.94 $95.83
Average True Range (ATR) 0.03 6.22
MACD -0.07 -1.23
Stochastic Oscillator 55.00 2.20

Price Performance

Historical Comparison
ADT
ORKA

About ADT ADT Inc.

ADT Inc is a provider of security, interactive, and smart home solutions serving consumer and small business customers in the United States (U.S.). The Company conducts business under the ADT brand name.

About ORKA Oruka Therapeutics Inc.

Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.

Share on Social Networks: